Bio-Techne Files Preliminary Proxy for $73/Share Merck KGaA Acquisition
TECH sits 67% above its 52-week low of $43.195.
Summary
Bio-Techne filed its preliminary proxy statement for the $73 per share all-cash acquisition by Merck KGaA, detailing the board's unanimous recommendation, the fairness opinion, and the competitive bidding process that led to the deal. The filing sets the stage for a shareholder vote on the $11.3 billion transaction.
Key Events · M&A and Partnerships · TECH
-
Merger Agreement at $73/Share
Bio-Techne entered into a definitive agreement to be acquired by Merck KGaA for $73.00 per share in cash, a 24% premium to the last undisturbed closing price of $58.88 on June 24, 2026. The total transaction value is approximately $11.3 billion.
-
Board Unanimously Recommends Approval
The Bio-Techne board unanimously determined the merger is in the best interests of shareholders, citing the certainty of cash consideration, the elimination of stand-alone risks, and the fairness opinion from Goldman Sachs.
-
Competitive Bidding Process
The proxy reveals a months-long process involving multiple bidders, with Merck KGaA increasing its offer from an initial $65 to $73 per share. Party B submitted a competing bid at $71 per share before pausing its pursuit.
-
Goldman Sachs Fairness Opinion
Goldman Sachs rendered a fairness opinion, supported by discounted cash flow analysis ($58-$72 per share), selected transactions analysis ($49-$67 per share), and premiums paid analysis ($67-$86 per share).
Analysis · TECH · Life Sciences
The preliminary proxy statement from Bio-Techne delivers the first in-depth account of the $73 per share all-cash acquisition by Merck KGaA, covering the board's rationale, Goldman Sachs' fairness opinion, management projections, and the negotiation background. It reveals that the $73 offer—a 24% premium to the undisturbed price—emerged from a competitive process with multiple bidders. The board unanimously recommends shareholders vote FOR the merger, emphasizing the certainty of cash consideration and the removal of stand-alone risks. The proxy also details substantial golden parachute payments for executives, with CEO Kim Kelderman potentially receiving over $52 million in merger-related compensation. The shareholder vote stands as the next critical milestone, with the meeting date yet to be set.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 52.5% of the 204 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.68%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TECH was trading at $72.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $43.20 to $72.39. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.